Liquidity & Technicals
Portfolio Implementation Verdict
DKS trades roughly $237M daily, giving institutional funds clear capacity to build or exit a 5% position within five trading days for portfolios up to ~$4.9B at 20% ADV participation. The tape is neutral with a bullish lean — price has reclaimed the 200-day SMA (+3%) after a February death cross, but the rally's MACD momentum is fading and the moving-average structure (SMA50 still well below SMA200) remains unresolved.
5-Day Capacity (20% ADV)
Max Position % Mkt Cap (5d)
Fund AUM for 5% Pos (20% ADV)
ADV 20d / Mkt Cap
Technical Score (+3 to −3)
Liquidity is adequate for mid-sized institutional portfolios, but shares outstanding and market cap are missing from the data source — liquidation-runway and capacity-as-%-of-market-cap figures are unavailable. Technical setup is mixed: price above 200d but death cross still active and MACD momentum fading.
Price Snapshot
Current Price
YTD Return
1-Year Return
52-Week Position
Beta
Full-History Price with 50/200 SMA
Price is above the 200-day SMA ($213.55) by 3.0%. This is an uptrend attempt from a deep drawdown. DKS collapsed from its 2021 highs near $255 into a multi-year consolidation range, then staged a powerful breakout in early 2024 (doubling from $130 to $230+), pulled back sharply through mid-2025 (touching $167), and has since rallied back above the 200d. The regime is transitional — no longer in a clear downtrend, but not yet in a confirmed uptrend.
Death cross on 2026-02-17 — SMA50 ($205) crossed below SMA200 ($214). A short-term golden cross (SMA20 over SMA50) fired on 2026-04-17, suggesting a recovery attempt, but the primary moving-average structure remains bearish until SMA50 reclaims SMA200.
Relative Strength vs Benchmark
Benchmark comparison series (SPY, XLY) are not available in the data source for this run. The chart shows DKS absolute rebased performance only. Over 3 years, DKS returned +50.9%, with the strongest phase in early 2024 (peaking at 169 on a rebased basis in Jan 2025) followed by a drawdown and partial recovery.
DKS has delivered strong absolute returns (+15.9% 1y, +47.3% 3y, +160.2% 5y), but without benchmark data, the relative-strength picture is incomplete. The key observation is the pattern: a sharp run-up through early 2025, a punishing drawdown to 119 (rebased) by mid-2025, and a grind back to ~151 today. The stock is not making new highs — it is recovering lost ground.
Momentum Panel — RSI + MACD
RSI at 56.5 is neutral — no overbought/oversold signal. The MACD histogram spiked to +2.76 in mid-April on the recovery rally, but has collapsed to +0.24 by April 29, indicating momentum is fading rapidly. The 1-to-3 month outlook depends on whether this MACD deceleration is a normal consolidation after a sharp move or the beginning of another rollover. If RSI fails to hold above 50 on the next pullback, the recovery attempt is likely exhausted.
Volume, Volatility, and Sponsorship
The three largest volume spikes all coincide with earnings releases — this is a name where the tape is earnings-driven, not flow-driven. The 50-day average volume has trended lower since mid-2025 (from ~1.8M to ~1.2M shares), consistent with a post-volatility normalization as the stock settled into a range. The April 2026 rally did not produce abnormal volume, which is a mild negative — it suggests the move was short-covering or low-conviction rather than fresh institutional accumulation.
Realized volatility at 29.7% sits right at the p20 boundary (28.7%) — the calm end of DKS's historical range. This is notable: the stock just rallied 15% in a month and vol is low. The last time vol was this compressed was late 2024, which preceded a sharp selloff. Low vol after a strong move is not inherently bearish, but it means the market is not pricing significant near-term risk — any earnings surprise or macro shock could produce an outsized move.
Institutional Liquidity Panel
A. ADV and Turnover
ADV 20d (Shares)
ADV 20d ($M)
ADV 60d (Shares)
ADV 20d / Mkt Cap (%)
Annual Turnover (%)
Shares outstanding and market cap are not available in the data source. ADV-to-market-cap, annual turnover, and liquidation-runway calculations cannot be completed. The raw ADV figures ($237M/day) indicate a liquid NYSE-listed name, but position sizing as a percentage of market cap must be verified independently.
B. Fund-Capacity Table
At 20% ADV participation, a fund can deploy $244.5M over five trading days. That supports a 5% portfolio weight for funds up to ~$4.9B, or a 2% weight for funds up to ~$12.2B. At the more conservative 10% ADV, a 5% weight is implementable for funds up to ~$2.4B.
C. Liquidation Runway
Liquidation runway cannot be computed — shares outstanding and market cap are missing from the data source. Based on publicly available information, DKS has a market cap in the mid-teens billions range. At $237M daily value traded, even a 1% market cap position (~$170M) would clear in under 4 days at 20% ADV participation.
D. Execution Friction
The 60-day median daily price range is 3.3%, which is elevated. Institutional orders in DKS should expect meaningful intraday slippage on large blocks. There were zero-volume days in the last 60 sessions: none — continuous trading confirmed.
Summary: The largest position that clears within 5 days at 20% ADV participation is approximately $244.5M. At 10% ADV, it is $122.2M. Liquidity is not the constraint for mid-sized funds, but the 3.3% daily range means impact cost is real for aggressive execution.
Technical Scorecard and Stance
Total: +3 out of ±6
Stance: Neutral with a bullish lean on the 3-to-6 month horizon. DKS has reclaimed the 200-day SMA after a sustained drawdown from $237 to $167, which is constructive. But the recovery is unconfirmed: the death cross is still active, the MACD histogram is fading, and the April rally occurred on declining volume. The tape is saying "recovery attempt" — not "new uptrend." The fundamental story (specialty retail with strong cash generation and a loyal customer base) supports the price, but the technical structure needs more time.
Level above: $237 — a break above the 52-week high confirms the recovery is real, resolves the death cross, and opens a path to the all-time high of $255.
Level below: $205 — a break below the SMA50 (currently $205) would put price back below both major moving averages, validate the death cross, and point toward a retest of the $167 low.
Liquidity is not the constraint. A 5% position is implementable for funds up to roughly $4.9B at 20% ADV participation over five days. The binding constraint is conviction: the tape has not confirmed the bullish reversal, and the right posture is either wait-for-confirmation or build slowly on pullbacks toward the 200d ($214).